672 related articles for article (PubMed ID: 18950515)
41. [Triple-negative breast carcinoma--rewiev of current literature].
Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
[TBL] [Abstract][Full Text] [Related]
42. Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers.
Koenders PG; Beex LV; Geurts-Moespot A; Heuvel JJ; Kienhuis CB; Benraad TJ
Cancer Res; 1991 Sep; 51(17):4544-8. PubMed ID: 1873798
[TBL] [Abstract][Full Text] [Related]
43. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.
Zhang Z; Yamashita H; Toyama T; Sugiura H; Ando Y; Mita K; Hamaguchi M; Hara Y; Kobayashi S; Iwase H
Breast Cancer Res Treat; 2005 Nov; 94(1):11-6. PubMed ID: 16172792
[TBL] [Abstract][Full Text] [Related]
44. EGFR expression and gene copy number in triple-negative breast carcinoma.
Gumuskaya B; Alper M; Hucumenoglu S; Altundag K; Uner A; Guler G
Cancer Genet Cytogenet; 2010 Dec; 203(2):222-9. PubMed ID: 21156237
[TBL] [Abstract][Full Text] [Related]
45. Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis.
Johansson I; Aaltonen KE; Ebbesson A; Grabau D; Wigerup C; Hedenfalk I; Rydén L
Genes Chromosomes Cancer; 2012 Apr; 51(4):375-83. PubMed ID: 22170730
[TBL] [Abstract][Full Text] [Related]
46. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.
DiGiovanna MP; Stern DF; Edgerton SM; Whalen SG; Moore D; Thor AD
J Clin Oncol; 2005 Feb; 23(6):1152-60. PubMed ID: 15718311
[TBL] [Abstract][Full Text] [Related]
47. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.
Tischkowitz M; Brunet JS; Bégin LR; Huntsman DG; Cheang MC; Akslen LA; Nielsen TO; Foulkes WD
BMC Cancer; 2007 Jul; 7():134. PubMed ID: 17650314
[TBL] [Abstract][Full Text] [Related]
48. Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC).
Cho EY; Chang MH; Choi YL; Lee JE; Nam SJ; Yang JH; Park YH; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2011 Sep; 68(3):753-61. PubMed ID: 21170648
[TBL] [Abstract][Full Text] [Related]
49. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.
Viale G; Rotmensz N; Maisonneuve P; Bottiglieri L; Montagna E; Luini A; Veronesi P; Intra M; Torrisi R; Cardillo A; Campagnoli E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2009 Jul; 116(2):317-28. PubMed ID: 18839307
[TBL] [Abstract][Full Text] [Related]
50. Human epidermal growth factor receptor 2, Na+/H+ exchanger regulatory factor 1, and breast cancer susceptibility gene-1 as new biomarkers for familial breast cancers.
Mangia A; Malfettone A; Saponaro C; Tommasi S; Simone G; Paradiso A
Hum Pathol; 2011 Nov; 42(11):1589-95. PubMed ID: 21496870
[TBL] [Abstract][Full Text] [Related]
51. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.
Hicks DG; Short SM; Prescott NL; Tarr SM; Coleman KA; Yoder BJ; Crowe JP; Choueiri TK; Dawson AE; Budd GT; Tubbs RR; Casey G; Weil RJ
Am J Surg Pathol; 2006 Sep; 30(9):1097-104. PubMed ID: 16931954
[TBL] [Abstract][Full Text] [Related]
52. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
[TBL] [Abstract][Full Text] [Related]
53. Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.
Zhang Z; Yamashita H; Toyama T; Yamamoto Y; Kawasoe T; Iwase H
Clin Cancer Res; 2006 Nov; 12(21):6410-4. PubMed ID: 17085653
[TBL] [Abstract][Full Text] [Related]
54. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
55. Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers.
Thor AD; Edgerton SM; Liu S; Moore DH; Kwiatkowski DJ
Clin Cancer Res; 2001 Aug; 7(8):2415-24. PubMed ID: 11489821
[TBL] [Abstract][Full Text] [Related]
56. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
Nanda R
Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
[TBL] [Abstract][Full Text] [Related]
57. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.
Biswas DK; Iglehart JD
J Cell Physiol; 2006 Dec; 209(3):645-52. PubMed ID: 17001676
[TBL] [Abstract][Full Text] [Related]
58. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.
Schlomm T; Kirstein P; Iwers L; Daniel B; Steuber T; Walz J; Chun FH; Haese A; Kollermann J; Graefen M; Huland H; Sauter G; Simon R; Erbersdobler A
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6579-84. PubMed ID: 18006757
[TBL] [Abstract][Full Text] [Related]
59. Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells.
deFazio A; Chiew YE; McEvoy M; Watts CK; Sutherland RL
Cell Growth Differ; 1997 Aug; 8(8):903-11. PubMed ID: 9269899
[TBL] [Abstract][Full Text] [Related]
60. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]